Dr Reddy's Labs announces conclusion of patent litigation with Indivior

30 Jun 2022 , 10:09 AM

Dr Reddy’s Laboratories Limited has announced about the conclusion of the patent litigation brought by Indivior Inc. and Indivior UK Limited, and Aquestive Therapeutics, Inc. relating to the Company’s generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages.

It is a therapeutic equivalent generic version of Suboxone sublingual film in U.S.A.

On June 28, 2022 the U.S. Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties.

Further as per the filing, the stipulation of dismissal was filed pursuant to a settlement agreement that the Company entered into with Indivior and Aquestive. The settlement and dismissal resolves all claims between the parties, including Indivior’s and Aquestive’s claims for patent infringement as well as the Company’s antitrust counterclaim against Indivior.

At around 10:11 AM, Dr Reddys Laboratories was trading at Rs4,364.05 per share up by Rs0.75 or 0.02% from its previous closing of Rs4,363.30 per share on the BSE.